Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report

S. Goldman; L. Smith; J. R. Anderson; S. Perkins; L. Harrison; M. B. Geyer; T. G. Gross; H. Weinstein; S. Bergeron; B. Shiramizu; W. Sanger; M. Barth; J. Zhi; M. S. Cairo

doi:10.1038/leu.2012.255

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report

S. Goldman, L. Smith, J. R. Anderson, S. Perkins, L. Harrison, M. B. Geyer, T. G. Gross, H. Weinstein, S. Bergeron, B. Shiramizu, W. Sanger, M. Barth, J. Zhi, M. S. Cairo

Research output: Contribution to journal › Letter › peer-review

92 Scopus citations

Original language	English (US)
Pages (from-to)	1174-1177
Number of pages	4
Journal	Leukemia
Volume	27
Issue number	5
DOIs	https://doi.org/10.1038/leu.2012.255
State	Published - May 2013

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2012.255

Cite this

Goldman, S., Smith, L., Anderson, J. R., Perkins, S., Harrison, L., Geyer, M. B., Gross, T. G., Weinstein, H., Bergeron, S., Shiramizu, B., Sanger, W., Barth, M., Zhi, J., & Cairo, M. S. (2013). Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report. Leukemia, 27(5), 1174-1177. https://doi.org/10.1038/leu.2012.255

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma : A Children's Oncology Group report. / Goldman, S.; Smith, L.; Anderson, J. R.; Perkins, S.; Harrison, L.; Geyer, M. B.; Gross, T. G.; Weinstein, H.; Bergeron, S.; Shiramizu, B.; Sanger, W.; Barth, M.; Zhi, J.; Cairo, M. S.

In: Leukemia, Vol. 27, No. 5, 05.2013, p. 1174-1177.

Research output: Contribution to journal › Letter › peer-review

Goldman, S, Smith, L, Anderson, JR, Perkins, S, Harrison, L, Geyer, MB, Gross, TG, Weinstein, H, Bergeron, S, Shiramizu, B, Sanger, W, Barth, M, Zhi, J & Cairo, MS 2013, 'Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report', Leukemia, vol. 27, no. 5, pp. 1174-1177. https://doi.org/10.1038/leu.2012.255

Goldman, S. ; Smith, L. ; Anderson, J. R. ; Perkins, S. ; Harrison, L. ; Geyer, M. B. ; Gross, T. G. ; Weinstein, H. ; Bergeron, S. ; Shiramizu, B. ; Sanger, W. ; Barth, M. ; Zhi, J. ; Cairo, M. S. / Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma : A Children's Oncology Group report. In: Leukemia. 2013 ; Vol. 27, No. 5. pp. 1174-1177.

@article{5f2710ceb23c4719aa94f72480d6824e,

title = "Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report",

author = "S. Goldman and L. Smith and Anderson, {J. R.} and S. Perkins and L. Harrison and Geyer, {M. B.} and Gross, {T. G.} and H. Weinstein and S. Bergeron and B. Shiramizu and W. Sanger and M. Barth and J. Zhi and Cairo, {M. S.}",

note = "Funding Information: VG, KF and MH received honoraria and travel grants from Roche. MH declared consultancy and board membership for Roche. GB, KH and MW are paid employees of Roche. The remaining authors declare no conflict of interest. Funding Information: We thank Linda Rahl, Virginia Davenport and Saumya Pachauri for their assistance in the development and conduct of this trial, and Ms Amber Quinlan and Erin Morris, RN, for their editorial assistance in the development of this manuscript. We would also like to thank Dr James Lynch for his assistance with analyzing the data. This research was funded by the Division of Cancer Treatment, National Cancer Institute, and National Institutes of Health, Department of Health and Human Services (COG) (CA98543-09 and CA98413-09), Pediatric Cancer Research Foundation and the Doris Duke Charitable Foundation. NCI provided support for data collection and analysis, but had no role in data interpretation, writing of the manuscript or the decision on journal submission.",

year = "2013",

month = may,

doi = "10.1038/leu.2012.255",

language = "English (US)",

volume = "27",

pages = "1174--1177",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma

T2 - A Children's Oncology Group report

AU - Goldman, S.

AU - Smith, L.

AU - Anderson, J. R.

AU - Perkins, S.

AU - Harrison, L.

AU - Geyer, M. B.

AU - Gross, T. G.

AU - Weinstein, H.

AU - Bergeron, S.

AU - Shiramizu, B.

AU - Sanger, W.

AU - Barth, M.

AU - Zhi, J.

AU - Cairo, M. S.

N1 - Funding Information: VG, KF and MH received honoraria and travel grants from Roche. MH declared consultancy and board membership for Roche. GB, KH and MW are paid employees of Roche. The remaining authors declare no conflict of interest. Funding Information: We thank Linda Rahl, Virginia Davenport and Saumya Pachauri for their assistance in the development and conduct of this trial, and Ms Amber Quinlan and Erin Morris, RN, for their editorial assistance in the development of this manuscript. We would also like to thank Dr James Lynch for his assistance with analyzing the data. This research was funded by the Division of Cancer Treatment, National Cancer Institute, and National Institutes of Health, Department of Health and Human Services (COG) (CA98543-09 and CA98413-09), Pediatric Cancer Research Foundation and the Doris Duke Charitable Foundation. NCI provided support for data collection and analysis, but had no role in data interpretation, writing of the manuscript or the decision on journal submission.

PY - 2013/5

Y1 - 2013/5

UR - http://www.scopus.com/inward/record.url?scp=84877619828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877619828&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.255

DO - 10.1038/leu.2012.255

M3 - Letter

C2 - 22940833

AN - SCOPUS:84877619828

VL - 27

SP - 1174

EP - 1177

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -